- Home
- MLCO vs BCRX Comparison
MLCO vs BCRX Comparison
Compare MLCO & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLCO | BCRX |
|---|---|---|
| Founded | 2003 | 1986 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2006 | 1995 |
Fundamental Metrics
Financial Performance| Metric | MLCO | BCRX |
|---|---|---|
| Price | $5.45 | $9.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $10.10 | ★ $20.82 |
| AVG Volume (30 Days) | 3.2M | ★ 6.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $4.37 | $12.55 |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.07 | $6.00 |
| 52 Week High | $10.15 | $11.22 |
Technical Indicators
Market Signals| Indicator | MLCO | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 45.60 |
| Support Level | $5.18 | $8.13 |
| Resistance Level | $5.71 | $9.61 |
| Average True Range (ATR) | 0.20 | 0.53 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 69.23 | 14.32 |
Price Performance
Historical ComparisonAbout MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.